133 related articles for article (PubMed ID: 38346600)
1. Ethanol-based solubility-enabling oral drug formulation development: Accounting for the solubility-permeability interplay.
Fine-Shamir N; Dahan A
Int J Pharm; 2024 Mar; 653():123893. PubMed ID: 38346600
[TBL] [Abstract][Full Text] [Related]
2. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Fine-Shamir N; Dahan A
Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
[TBL] [Abstract][Full Text] [Related]
3. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
Beig A; Miller JM; Lindley D; Dahan A
Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848
[TBL] [Abstract][Full Text] [Related]
4. The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation.
Fine-Shamir N; Beig A; Miller JM; Dahan A
Int J Pharm; 2020 May; 582():119307. PubMed ID: 32276090
[TBL] [Abstract][Full Text] [Related]
5. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
6. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
Dahan A; Beig A; Lindley D; Miller JM
Adv Drug Deliv Rev; 2016 Jun; 101():99-107. PubMed ID: 27129443
[TBL] [Abstract][Full Text] [Related]
7. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
[TBL] [Abstract][Full Text] [Related]
8. Active intestinal drug absorption and the solubility-permeability interplay.
Porat D; Dahan A
Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
[TBL] [Abstract][Full Text] [Related]
9. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.
Dahan A; Miller JM
AAPS J; 2012 Jun; 14(2):244-51. PubMed ID: 22391790
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
Beig A; Agbaria R; Dahan A
PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
[TBL] [Abstract][Full Text] [Related]
12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
13. Solubility-enabling formulations for oral delivery of lipophilic drugs: considering the solubility-permeability interplay for accelerated formulation development.
Fine-Shamir N; Dahan A
Expert Opin Drug Deliv; 2024; 21(1):13-29. PubMed ID: 38124383
[TBL] [Abstract][Full Text] [Related]
14. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
15. Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems.
Fine-Shamir N; Beig A; Dahan A
Int J Pharm; 2021 Mar; 597():120295. PubMed ID: 33497706
[TBL] [Abstract][Full Text] [Related]
16. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin.
Kristin F; René H; Boontida M; Buraphacheep JV; Maximilian A; Johanna M; Peter L
Eur J Pharm Sci; 2017 Apr; 101():211-219. PubMed ID: 28179133
[TBL] [Abstract][Full Text] [Related]
17. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
[TBL] [Abstract][Full Text] [Related]
18. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
[TBL] [Abstract][Full Text] [Related]
19. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
[TBL] [Abstract][Full Text] [Related]
20. Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility-Permeability Interplay.
Beig A; Lindley D; Miller JM; Agbaria R; Dahan A
Front Pharmacol; 2016; 7():379. PubMed ID: 27826241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
